var data={"title":"Levodopa and benserazide (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Levodopa and benserazide (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5713?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=levodopa-and-benserazide-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Levodopa and benserazide (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139718\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Prolopa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139728\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139721\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Parkinson disease: Adults &ge;25 years: </b>Oral: <b>Note:</b> Dosage should be introduced gradually, individualized, and continued for 3 to 6 weeks before assessing benefit. Levodopa 200 mg/benserazide 50 mg capsules should be used only when maintenance therapy is reached. Levodopa 50 mg/benserazide 12.5 mg capsules should be used to minimize adverse effects when adjusting dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patients currently receiving levodopa therapy:</i> Discontinue levodopa &ge;12 hours prior to the initiation of therapy; start at 15% of previous levodopa dose. After maintenance dose of levodopa/benserazide is established, slowly decrease dose of levodopa by 50 mg per month over a few months until a maintenance dose without dyskinesias is achieved. Total daily dose of levodopa during the first year of therapy with levodopa/benserazide should not exceed 1,000 mg to 1,200 mg/day. After 1 year of therapy, the maximum recommended daily dose of levodopa is 600 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patients <b>NOT</b> on levodopa therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initiation: Levodopa 100 mg/benserazide 25 mg once or twice daily; increase dose by levodopa 100 mg/benserazide 25 mg every 3 to 4 days or slower (eg, weekly) if problems with tolerance until adequate therapeutic effect without dyskinesias; reduce frequency of dosage adjustments to every 2 to 4 weeks as upper limits of dosing range is approached.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual maintenance dosage: Levodopa 400 mg/benserazide 100 mg to levodopa 800 mg/benserazide 200 mg daily given in 4 to 6 divided doses; after maintenance dose of levodopa/benserazide is established, slowly decrease dose of levodopa by 50 mg per month over a few months until a maintenance dose without dyskinesias is achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum: Total daily dose of levodopa during the first year of therapy should not exceed 1,000 mg to 1,200 mg/day. Following first year, the maximum recommended daily dose of levodopa is 600 mg/day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990779\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling. Use in decompensated renal disease is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987954\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling. Use in decompensated hepatic disease is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2564095\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46730696\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patients experiencing dystonia:</i> There are no specific dosage recommendations provided in the manufacturer&rsquo;s labeling however a levodopa dose reduction is recommended; may also consider adjusting the dosing frequency. <b>Note:</b> Dystonias may appear earlier in levodopa/benserazide therapy than with levodopa alone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Interruption of therapy:</i> Following an extended interruption of therapy reinitiate at a reduced dose and adjust gradually. Following a brief interruption of therapy, may reinitiate therapy at previous dose when patient is able to resume treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950025\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prolopa:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">50-12.5: Levodopa 50 mg and benserazide 12.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">100-25: Levodopa 100 mg and benserazide 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">200-50: Levodopa 200 mg and benserazide 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217268\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139697\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with or immediately after meals. Administer with meals or a small snack if GI upset occurs. Capsules should be swallowed whole; do not crush, chew, open, or dissolve in liquid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139696\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease: </b>Treatment of Parkinson disease (except drug-induced Parkinsonism)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116829\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139685\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Arrhythmias, chest pain, ECG changes (nonspecific), edema, flushing, hypertension, orthostatic hypotension, pallor, phlebitis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation, anxiety, ataxia, bruxism, confusion, delusions, dementia, depression, dopamine dysregulation syndrome, euphoria, faintness, fatigue, fever, gait abnormalities, hallucinations (mostly visual), headache, impulse control symptoms (including pathological gambling), insomnia, lethargy, malaise, neuroleptic malignant-like syndrome, nightmares, oculogyric crisis, on-off phenomena, paranoid ideation, psychotic episodes, sedation, seizures, somnolence, suicidal tendencies/behavior, temporal disorientation, trismus </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatological: Alopecia, pruritus, rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Libido increased, protein-bound iodine increased, uric acid increased</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distress or pain, anorexia, burning sensation on tongue, constipation, diarrhea, duodenal ulcer, dysphagia, epigastric pain, eructation, flatulence, GI bleeding, nausea, sialorrhea, taste alterations, vomiting, weight gain/loss, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Discoloration of urine, hematuria, nocturia, urinary frequency, urinary retention or incontinence </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia (rare), leukopenia (transient), Positive Coombs' test, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Alkaline phosphatase increased, bilirubin increased, LDH increased, transaminases increased </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Akinesia paradoxica, choreiform and involuntary movements, dystonia, end-of-dose akinesia, hand tremor, low back pain, muscle spasm and twitching, musculoskeletal pain, numbness, torticollis, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Activation of latent Horner's syndrome, blepharospasm, blurred vision, diluted pupils, diplopia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: BUN increased </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bizarre breathing pattern, cough, hoarseness, postnasal drip </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Diaphoresis, discoloration of sweat, hiccups, hypersensitivity reactions,  lip/mouth/tongue tightness </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139700\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to benserazide, levodopa,  or any component of the formulation; use with or within 14 days of MAO inhibitors; when administration of a sympathomimetic amine (eg, epinephrine, norepinephrine, isoproterenol) is contraindicated; clinical or laboratory evidence of decompensated cardiovascular, endocrine, renal, hepatic, hematologic, or pulmonary disease; psychiatric diseases with a psychotic component; angle-closure glaucoma; patients &lt;25 years of age; pregnancy or use in women of childbearing potential without adequate contraception</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139683\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: <b>[Canadian Boxed Warning]: Patients have reported falling asleep while engaging in activities of daily living including the driving of a car; in some cases, these events have occurred without significant warning signs.</b> Monitor for daytime somnolence or preexisting sleep disorder; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents. Effects with other sedative drugs or ethanol may be potentiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions may occur in susceptible patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased growth hormone levels: May increase human growth hormone levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (MI, atrial, nodal, or ventricular arrhythmias); initiate in a monitored setting. Use is contraindicated in decompensated cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; monitor blood glucose frequently. Antidiabetic agents may require dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with chronic wide-angle glaucoma; monitor IOP carefully. Use is contraindicated in patients with angle-closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Use is contraindicated in decompensated hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychotic disorders: Use with extreme caution in patients with a history of psychotic disorders; observe patients closely for development of depression with concomitant suicidal tendencies. May also cause hallucinations and confusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Use is contraindicated in decompensated renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more sensitive to CNS effects of levodopa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perioperative patients: Continue therapy as close to surgical procedures as possible in patients requiring general anesthesia (excluding halothane-risk of blood pressure fluctuations and/or arrhythmias; discontinue benserazide/levodopa 12 to 48 hours before procedure); resume therapy postoperatively with a gradual increase in dose up to that established preoperatively.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Young adults: Use is contraindicated in patients &lt;25 years of age. Animal data suggests the possibility of skeletal abnormalities if benserazide is administered before ossification is complete.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse: May induce dopaminergic dysregulation syndrome resulting in excessive use of levodopa/benserazide beyond prescribed doses, particularly in males with early onset Parkinson disease (Giovannoni 2000); may lead to cognitive and behavioral disturbances. Monitor for excessive use if cognitive/behavioral disturbances develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not indicated in management of intention tremor, Huntington's chorea, or drug-induced extrapyramidal symptoms. Administer in careful increments and observe closely for development of abnormal involuntary movements.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Avoid abrupt withdrawal of therapy; dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome (NMS) on abrupt withdrawal or significant dosage reduction after long-term use. Withdraw therapy gradually and monitor closely; symptomatic patients should be treated appropriately and if necessary resumption of benserazide/levodopa therapy may be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298828\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139687\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9796&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Biperiden: May enhance the adverse/toxic effect of Levodopa. Specifically, the risk of choreic movements or dyskinesias may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May decrease the serum concentration of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Levodopa may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methionine: May diminish the therapeutic effect of Levodopa. Probably only with large doses of methionine.  Data was generated using 4.5gm daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: Levodopa may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.  Management: The concomitant use of nonselective monoamine oxidase inhibitors (MAOIs) and levodopa is contraindicated. Discontinue the nonselective MAOI at least two weeks prior to initiating levodopa. Monitor patients taking a selective MAOIs and levodopa.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Papaverine: May enhance the hypotensive effect of Levodopa. Papaverine may diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridoxine: May diminish the therapeutic effect of Levodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: May enhance the adverse/toxic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139713\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High protein diets have the potential to impair levodopa absorption; levodopa competes with certain amino acids for transport across the gut wall or across the blood-brain barrier. Management: Avoid high protein diets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Food reduces the extent of levodopa absorption by 15% and peak plasma concentrations by 30%.. Management: Administer with or immediately after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139703\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated during pregnancy and in women of childbearing potential without proper contraception.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events have been observed with levodopa in animal reproduction studies. Levodopa crosses the placenta and can be metabolized by the fetus and detected in fetal tissue (Merchant 1995). The incidence of Parkinson disease in pregnancy is relatively rare and information related to the use of benserazide/levodopa in pregnant women is limited (Hagell 1998; von Graevenitz 1996). The manufacturer recommends that women who become pregnant during therapy gradually taper off therapy; avoid abrupt withdrawal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139704\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Levodopa is excreted into breast milk (based on a study using carbidopa/levodopa) (Thulin, 1998); excretion of benserazide is not known. Breast-feeding is not recommended by the manufacturer. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139705\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">High-protein diets may decrease effect of levodopa.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139692\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Regular assessment of cardiovascular, hepatic, hematopoietic, and renal function with initiation and during dose stabilization then periodically with extended therapy; blood glucose frequently in patients with diabetes; symptoms of psychosis and dystonia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139682\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Symptoms of Parkinson disease are due to a lack of striatal dopamine. Levodopa crosses into the blood-brain barrier (BBB) and is converted to dopamine by striatal enzymes. Benserazide inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation and therefore increases levodopa availability at the BBB.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139699\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Benserazide: 66% to 74% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benserazide: Does not cross the blood-brain barrier; mainly concentrated in kidneys, liver, lungs, and small intestine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levodopa: 57 L; crosses the blood-brain barrier and not bound to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Benserazide: Hydroxylated in the intestine and liver to trihydroxybenzylhydrazine, a potent inhibitor of decarboxylase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Levodopa: Major pathways: Decarboxylation to dopamine and O-methylation to 3-O-methyldopa; Minor pathways; Transamination and oxidation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Levodopa: 98% (range: 74% to 112%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Levodopa: 1.5 hours; 3-O-methyldopa (major metabolite): 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Levodopa: ~1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Benserazide: Urine (64%); feces (24%); Levodopa: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F139706\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cenparkin (TH, TW);</li>\n      <li>Dopamed (AT);</li>\n      <li>Eugenix (ID);</li>\n      <li>Levazide (ID);</li>\n      <li>Levoben (ID);</li>\n      <li>Levopar (DE, ID, TH);</li>\n      <li>Levopar Plus (IL);</li>\n      <li>Madopar (AE, AR, AT, AU, BH, CH, CN, CO, CR, CZ, DE, DK, DO, EE, EG, ES, FI, GB, GR, GT, HK, HN, HR, IE, IN, IS, IT, KR, KW, LB, LT, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SG, SI, SK, SV, TH, TR, TW, VE, VN);</li>\n      <li>Madopar-F (IN);</li>\n      <li>Madopark (SE);</li>\n      <li>Modopar (FR);</li>\n      <li>Prolopa (BE, BR, PY, UY);</li>\n      <li>Prolopar (CL);</li>\n      <li>Seler (PY);</li>\n      <li>Tonotil (UY);</li>\n      <li>Vopar (HK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Giovannoni G, O&rsquo;Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson&rsquo;s disease on dopamine replacement therapies. <i>J Neurol Neurosurg Psychiatry.</i> 2000;68(4):423-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/10727476/pubmed\" target=\"_blank\" id=\"10727476\">10727476</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hagell P, Odin P, and Vinge E, &quot;Pregnancy in Parkinson's Disease: A Review of the Literature and a Case Report,&quot; <i>Mov Disord</i>, 1998, 13(1):34-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/9452323/pubmed\" target=\"_blank\" id=\"9452323\">9452323</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merchant CA, Cohen G, Mytilineou C, et al, &quot;Human Transplacental Transfer of Carbidopa/Levodopa,&quot; <i>J Neural Transm Park Dis Dement Sect</i>, 1995, 9(2-3):239-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/8527007/pubmed\" target=\"_blank\" id=\"8527007\">8527007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo; <i>Mov Disord</i>, 2000, 15(5):869-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/11009192/pubmed\" target=\"_blank\" id=\"11009192\">11009192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prolopa (levodopa/benserazide) [product monograph]. Mississauga, Ontario, Canada: Hoffman-La Roche Limited; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thulin PC, Woodward WR, Carter JH, et al, &quot;Levodopa in Human Breast Milk: Clinical Implications,&quot; <i>Neurology</i>, 1998, 50(6):1920-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/9633767/pubmed\" target=\"_blank\" id=\"9633767\">9633767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Graevenitz KS, Shulman LM, and Revell SP, &quot;Levodopa in Pregnancy,&quot; <i>Mov Disord</i>, 1996, 11(1):115-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/levodopa-and-benserazide-united-states-not-available-drug-information/abstract-text/8771087/pubmed\" target=\"_blank\" id=\"8771087\">8771087</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9796 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F139718\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F139728\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F139721\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990779\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987954\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2564095\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F46730696\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950025\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217268\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F139697\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F139696\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26116829\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F139685\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F139700\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F139683\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298828\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F139687\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F139713\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F139703\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F139704\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F139705\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F139692\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F139682\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F139699\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F139706\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9796|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=levodopa-and-benserazide-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Levodopa and benserazide (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}